A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

This is a Phase II clinical study to evaluate the efficacy and safety of intravesical T3011 injection in participants with BCG-unresponsive high-risk NMIBC or BCG-exposed, chemotherapy-unresponsive intermediate/high-risk NMIBC.

Trial Details

NCT ID
NCT06971614
Phase
PHASE2
Sponsor
ImmVira Pharma Co. Ltd
Status
RECRUITING
Cancer Type
Bladder Cancer
Interventions
  • T3011
Locations (sample)
  • Queen Creek, Arizona, United States|33.24866,-111.6343
  • Los Angeles, California, United States|34.05223,-118.24368
  • Orlando, Florida, United States|28.53834,-81.37924
  • Tampa, Florida, United States|27.94752,-82.45843
  • New Brunswick, New Jersey, United States|40.48622,-74.45182

Key Eligibility Criteria

  • Participants may enter the study only if they meet all the following criteria:
  • Male or female, aged ≥18 years at the time of signing the ICF.
  • The participants will need to meet the following criteria:
  • Participants with a histologically confirmed diagnosis of NMIBC (Ta, T1 and/or Cis).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Bladder Cancer Trials on Trialify →